ICON CLINICAL RESEARCH LIMITED

Their core work

ICON is a large Irish contract research organization (CRO) that provides clinical trial management and regulatory services for pharmaceutical and biotech companies. Within H2020, they contributed clinical trial design, patient data management, and regulatory expertise to multi-center studies — particularly in neurodegenerative diseases, cell therapy, and digital health outcomes. Their role is to ensure that experimental therapies move through rigorous clinical phases (Phase II and III) with proper methodology, patient recruitment, and regulatory compliance.

What they specialise in

How they've shifted over time

ICON's early H2020 involvement (2015-2017) centered on traditional clinical trial execution — a Phase II randomized controlled trial for ALS using low-dose interleukin-2 immunotherapy (MIROCALS), plus early-stage cell therapy studies. From 2018 onward, their focus shifted toward two directions: scaling cell therapy trials to Phase III (HIPGEN for hip fracture recovery) and embracing digital health outcomes and connected care models (MOBILISE-D, CareHD). This evolution reflects the broader pharma industry's move toward digital endpoints and real-world evidence alongside conventional clinical trials.

ICON is moving toward digital mobility assessment and connected health models, positioning them well for projects that need clinical validation of digital biomarkers and real-world patient monitoring.

How they like to work

ICON operates exclusively as a participant, never coordinating — consistent with their role as a CRO providing specialized clinical trial services to investigator-led consortia. With 94 unique partners across 19 countries, they connect into large, diverse consortia rather than working in tight clusters. This makes them an accessible and experienced partner who integrates smoothly into multi-national clinical research projects without competing for the scientific lead.

ICON has collaborated with 94 unique partners across 19 countries, reflecting the large multi-center clinical trial consortia they typically join. Their network spans broadly across Europe with no strong geographic concentration, consistent with their role as a global CRO headquartered in Dublin.

What sets them apart

ICON brings industrial-grade clinical trial infrastructure to academic-led EU research projects — something most university hospitals and research institutes cannot replicate internally. As one of the world's largest CROs, they offer regulatory expertise, multi-site trial coordination, and patient data management at a scale that de-risks ambitious translational studies. For consortium builders, ICON is the partner that turns a promising therapy concept into a properly powered, regulatory-compliant clinical study.

Highlights from their portfolio

• HIPGEN
  Largest funding (EUR 1.25M) — a Phase III clinical study of placenta-derived cell therapy for hip fracture recovery, representing ICON's most advanced trial management role.
• MOBILISE-D
  Ambitious multi-disease digital mobility assessment project spanning COPD, Parkinson's, MS, and hip fracture cohorts — signals ICON's move into digital clinical endpoints.
• MIROCALS
  Pioneering Phase II RCT testing low-dose interleukin-2 immunotherapy for ALS — a first-in-class anti-neuroinflammatory approach for a disease with few treatment options.